Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.36 |
| ▸ | F12 | P00748 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 4/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16622327 | 0.91 | C5AR1 (0.37) | ADORA1C5AR1NR1H2 | |
| SCHEMBL3457767 | 0.88 | F12 (0.33) | ADORA1C5AR1F12NR1H2 | |
| SCHEMBL19201023 | 0.87 | C5AR1 (0.32) | C5AR1F12 | |
| SCHEMBL19312086 | 0.84 | C5AR1 (0.35) | ADORA1C5AR1 | |
| SCHEMBL18871752 | 0.84 | TSHR (0.34) | ADORA1TSHRALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL3331339 | 0.82 | C5AR1 (0.34) | ADORA1C5AR1 | |
| SCHEMBL6375680 | 0.82 | C5AR1 (0.35) | ADORA1C5AR1F12NR1H2 | |
| SCHEMBL1206431 | 0.81 | C5AR1 (0.41) | ADORA1C5AR1F12NR1H2 | |
| SCHEMBL17970047 | 0.80 | TSHR (0.33) | TSHRALDH1A1HPGDSMN1; SMN2NPSR1 | |
| SCHEMBL10084846 | 0.80 | TSHR (0.33) | TSHRALDH1A1HPGDSMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12491251-B2 | Degraders of cyclin-dependent kinase 7 (CDK7) and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-12-09 | — | — | US | disclosed |
| EP-3236959-B1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA FARBER CANCER INST INC (US) | 2025-09-24 | — | — | EP | disclosed |
| US-12281126-B2 | Inhibitors of cyclin-dependent kinase 7 and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| EP-4010336-B1 | DEGRADERS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2025-04-02 | — | — | EP | disclosed |
| US-12168663-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| US-11780853-B2 | Substituted N-pyrimidin-4-yl-3-aminopyrrolo[3,4-C]pyrazoles as protein kinase C inhibitors | PFIZER INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780853-B2 | Substituted N-pyrimidin-4-yl-3-aminopyrrolo[3,4-C]pyrazoles as protein kinase C inhibitors | PFIZER INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780853-B2 | Substituted N-pyrimidin-4-yl-3-aminopyrrolo[3,4-C]pyrazoles as protein kinase C inhibitors | PFIZER INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230242534-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230242534-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| EP-2118112-A1 | 3-AMINO-PYRROLO[3,4-C] PYRAZOLE- 5 (1H, 4H, 6H) CARBALDEHYDE DERIVATIVES AS PKC INHIBITORS | Pfizer Inc. (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20090082346-A1 | Substituted Pyrrolo-Pyrazole Derivatives as Kinase Inhibitors | PFIZER ITALIA S.R.L. (IT) | 2009-03-26 | — | — | US | disclosed |
| WO-2008125945-A2 | 3-AMIDO-PYRROLO [3, 4-C] PYRAZOLE-5 (1H, 4H, 6H) CARBALDEHYDE DERIVATIVES AS INHIBITORS OF PROTEIN KINASE C | PFIZER INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008096260-A1 | 3-AMINO-PYRROLO[3,4-C] PYRAZOLE- 5 (1H, 4H, 6H) CARBALDEHYDE DERIVATIVES AS PKC INHIBITORS | PFIZER INC. (US) | 2008-08-14 | — | — | WO | disclosed |
| US-7407971-B2 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2008-08-05 | — | — | US | disclosed |
| EP-1838718-A1 | PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | Pfizer, Inc. (US) | 2007-10-03 | — | — | EP | disclosed |
| US-20070004705-A1 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-01-04 | — | — | US | disclosed |
| WO-2006072831-A1 | PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | PFIZER INC. (US) | 2006-07-13 | — | — | WO | disclosed |
| EP-1575954-A2 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004056827-A2 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780853-B2 | Substituted N-pyrimidin-4-yl-3-aminopyrrolo[3,4-C]pyrazoles as protein kinase C inhibitors | PRKCB, PRKCA, PRKCQ | ADORA1 597/4885C5AR1 1133/4885F12 1129/4885 |
| US-12168663-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK3, CDK9 | ADORA1 3076/4885C5AR1 2348/4885F12 941/4885 |
| US-20070004705-A1 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | CCNI, CDK1, CDK2 | ADORA1 3645/4885C5AR1 4797/4885F12 1931/4885 |
| US-12281126-B2 | Inhibitors of cyclin-dependent kinase 7 and uses thereof | CDK9, CDK7, CDK1 | ADORA1 4696/4885C5AR1 3994/4885F12 1512/4885 |
| US-12491251-B2 | Degraders of cyclin-dependent kinase 7 (CDK7) and uses thereof | CDK7, CDK8, CDK17 | ADORA1 4117/4885C5AR1 2858/4885F12 3377/4885 |
| US-20230242534-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 AND USES THEREOF | CDK2, CDK5, CDK9 | ADORA1 1850/4885C5AR1 700/4885F12 1123/4885 |
| US-20090082346-A1 | Substituted Pyrrolo-Pyrazole Derivatives as Kinase Inhibitors | CCNI, CDK1, CDK2 | ADORA1 3645/4885C5AR1 4797/4885F12 1931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.